ArticleInflammation research : official journal of the European Histamine Research Society ... [et al.]2026
IGF2BP1 modulates ZDHHC5-mediated NLRP3 inflammasome activation to promote mitochondrial damage and foam cell formation of vascular smooth muscle cells.
Article in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- NLRP3 inflammasome in acute kidney injury: molecular mechanisms, post-translational regulation, and immunotherapeutic potential.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundSmooth muscle-derived foam cell formation is a key to atherosclerosis (AS) development. Mitochondrial damage is involved in AS pathogenesis S. Here, effects of ZDHHC5 on mitochondrial damage and foam cell formation of vascular smooth muscle cells were evaluated.
methodsExpressions of mRNA and protein were determined by RT-qPCR and Western blot. ORO and Nile red staining evaluated foam cell formation. Mito tracker Green and Mito Tracker Red probes evaluated mitochondrial integrity. Electron microscopy observed mitochondrial morphology. Cytoplasmic mtDNA was quantified by mtDNA release assay. Acyl-biotin exchange assay tested palmitoylation level. Co-immunoprecipitation (Co-IP) detected interaction between ZDHHC5 and NLRP3. RNA immunoprecipitation (RIP) and RNA pull down verified interaction between ZDHHC5 and IGF2BP1. Methylated RNA immunoprecipitation (MeRIP) assessed m6A level on ZDHHC5. ApoE
resultsNLRP3 depletion reduced damage to mitochondria within foam cells derived from smooth muscle. Inhibiting NLRP3 palmitoylation hindered NLRP3 inflammasome activation. ZDHHC5 triggered NLRP3 activation through enhancing NLRP3 palmitoylation. ZDHHC5 exacerbated mitochondrial damage via activating NLRP3 inflammasome. IGF2BP1 enhanced stability and expression of ZDHHC5 mRNA in a m6A-dependent way. IGF2BP1 triggered NLRP3-mediated mitochondrial damage and amplified AS by upregulating ZDHHC5 in ApoE
conclusionsIGF2BP1 regulates ZDHHC5-mediated NLRP3 inflammasome activation, thereby enhancing mitochondrial damage and foam cell formation in vascular smooth muscle cells, which provides new therapeutic targets for AS.
Indexed as
Identifiers
42435226What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.